Company Overview - Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing therapies for challenging diseases, having introduced the first new class of complement medicine in 15 years [3] - The company has two approved medicines targeting C3, including the first-ever therapy for geographic atrophy, a leading cause of blindness globally [3] Upcoming Events - The company will host a conference call and webcast to discuss its second quarter 2025 financial results on July 31, 2025, at 8:30 a.m. ET [1] - A live audio webcast and accompanying slides will be available on the company's website, with a replay accessible for 90 days post-event [2]

Company Announcement - Apellis Pharmaceuticals, Inc. will present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025, at 10:40 a.m. ET [1] - A live conference webcast will be available on the company's website, with a replay accessible for approximately 90 days post-event [1] Company Overview - Apellis Pharmaceuticals is a global biopharmaceutical company focused on developing therapies for challenging diseases [2] - The company has introduced the first new class of complement medicine in 15 years, with two approved medicines targeting C3 [2] - Apellis has launched the first-ever therapy for geographic atrophy, a major cause of blindness globally, and aims to explore the potential of targeting C3 in various serious diseases [2]

Core Viewpoint - Apellis Pharmaceuticals, Inc. will host a conference call and webcast to discuss its first quarter 2025 financial results on May 7, 2025, at 8:30 a.m. ET [1] Company Overview - Apellis Pharmaceuticals is a global biopharmaceutical company focused on developing therapies for challenging diseases, having introduced the first new class of complement medicine in 15 years [3] - The company has two approved medicines targeting C3, including the first-ever therapy for geographic atrophy, a major cause of blindness globally [3] - Apellis believes it has only begun to unlock the potential of targeting C3 across various serious diseases [3]